四川汇宇制药股份有限公司 董事会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 四川汇宇制药股份有限公司（以下简称"公司"）第二届董事会第十九次会议 于 2025 年 9 月 26 日以通讯表决方式在公司会议室召开。会议通知和会议资料已 于 2025 年 9 月 22 日以电子邮件方式发出，经全体董事一致同意，本次会议豁免 通知期限。本次会议由董事长丁兆先生主持，会议应出席董事 9 人，实际出席董 事 9 人，相关高管列席。本次董事会会议的召集、召开程序符合《中华人民共和 国公司法》等法律法规以及《公司章程》的有关规定，作出的决议合法、有效。 证券代码：688553 证券简称：汇宇制药 公告编号：2025-078 具体内容详见公司披露于上海证券交易所网站（www.sse.com.cn）的《汇宇 制药关于拟为全资子公司提供担保的公告》。 （二）审议通过《关于制定公司<境外投资管理办法>的议案》 表决结果：9 票同意，0 票反对，0 票弃权。 具体内容请详见公司披露于上海证券交易所网站（ww ...

2024年，公司实现营业收入10.94亿元，同比增长18.05%；归属于上市公司股东的净利润为3.25亿元， 同比增长132.78%；归属于上市公司股东的扣除非经常性损益的净利润为9,211.71万元，同比增长 39.55%；经营活动产生的现金流量净额为2.43亿元，同比增长262.98%。 2025年1-6月，公司实现营业收入4.53亿元，同比下降14.86%；归属于上市公司股东的净利润为-8,072.05 万元，上年同期为6,521.34万元；归属于上市公司股东的扣除非经常性损益的净利润为4,807.31万元，同 比增长11.56%；经营活动产生的现金流量净额为-2,706.57万元，上年同期为4,044.55万元。 2021年10月26日，汇宇制药在上交所科创板上市，公开发行股票6360.00万股，发行价格为38.87元/股， 保荐机构、主承销商为中信建投（601066）证券，保荐代表人为杨泉、田斌，联席主承销商为国都证 券。 上市当日，汇宇制药盘中最高报42.59元，创上市以来股价最高点。 汇宇制药发行募集资金总额为24.72亿元，扣除发行费用后，募集资金净额为23.61亿元。汇宇制药最终 募集资金净 ...

中国经济网北京9月26日讯 汇宇制药(688553.SH)今日收报22.30元，跌幅6.14%。目前该股处于破发 状态。 汇宇制药发行费用合计1.11亿元，其中中信建投证券、国都证券获得承销费9887.48万元。 2021年至2023年，公司营业收入分别为18.24亿元、14.93亿元、9.27亿元，归属于上市公司股东的 净利润分别为4.46亿元、2.49亿元、1.40亿元，归属于上市公司股东的扣除非经常性损益的净利润分别 为4.10亿元、1.98亿元、6,601.06万元，经营活动产生的现金流量净额分别为4.46亿元、1.94亿元、 6,693.27万元。 2024年，公司实现营业收入10.94亿元，同比增长18.05%；归属于上市公司股东的净利润为3.25亿 元，同比增长132.78%；归属于上市公司股东的扣除非经常性损益的净利润为9,211.71万元，同比增长 39.55%；经营活动产生的现金流量净额为2.43亿元，同比增长262.98%。 2025年1-6月，公司实现营业收入4.53亿元，同比下降14.86%；归属于上市公司股东的净利润 为-8,072.05万元，上年同期为6,521.34万元；归属于 ...

Group 1 - The pharmaceutical sector in both A-shares and Hong Kong stocks experienced a collective decline on September 26 [1] - In A-shares, Sunflower dropped by 10%, while Guangsheng Tang and Aosaikang fell over 8%. Other companies like Jimin Health, Hanyu Pharmaceutical, Wanbangde, Hengrui Medicine, and Huiyu Pharmaceutical also saw declines [1] - In Hong Kong stocks, WuXi AppTec decreased by over 5%, BeiGene fell by more than 4%, and Fosun Pharma dropped nearly 2% [1]

按上一交易日公司收盘价25.01元计算，王晓鹏拟减持套现合计约317,827,080元。 截至公告披露日，王晓鹏持有汇宇制药股份数量为17,037,557股，占公司总股本的4.022%；上述股 份来源于公司首次公开发行前取得的股份，且已于2022年10月26日起解除限售并上市流通。 本次减持计划实施不会导致公司控制权发生变更。 中国经济网北京9月25日讯 汇宇制药(688553.SH)昨日晚间披露《股东减持股份计划公告》。 根据公告，股东王晓鹏拟通过集中竞价和大宗交易的方式合计减持公司股份不超过12,708,000股， 合计减持比例不超过公司股份总数的3%。减持期间为自公告披露之日起15个交易日后的3个月内，即 2025年10月24日至2026年1月21日。 其中以集中竞价方式减持所持股份数量不超过4,236,000股；以大宗交易方式减持所持股份数量不超 过8,472,000股。 王晓鹏为公司第三大股东、发起人。招股书显示，汇宇制药前身为汇宇有限，由丁兆、茂源神华、 王晓鹏、余波于2010年10月共同设立，注册资本5,000万元。 2021年10月26日，汇宇制药在上交所科创板上市，公开发行股票6360.00 ...

Key Points - Huasoft Technology is currently producing and selling light initiator products in small batches based on customer orders [1] - Kaineng Health plans to establish a wholly-owned subsidiary in Hainan or Hunan provinces to engage in the cell industry and related mergers and acquisitions [1] - Linyang Energy has won a bid for a 142 million yuan project with the State Grid [1] - New Zhizhi Software intends to acquire 49% equity of Shenzhen Hengdao for 48.2356 million yuan [1] - Xindian Software plans to repurchase shares worth between 30 million to 50 million yuan [1] - Shanjin International has submitted an application for the issuance and listing of H-shares on the Hong Kong Stock Exchange [1] - Zhongwei Semiconductor has also submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange [1] - Huadong Heavy Machinery's Wu Qingming Yu No. 6 and Tianchen Jinting No. 1 plan to reduce their holdings by no more than 1.5% [2] - Xinde New Materials' Shang Rong Baoying and its concerted parties plan to reduce their holdings by no more than 3% [2] - Huayi Pharmaceutical's shareholder Wang Xiaopeng plans to reduce his holdings by no more than 12.708 million shares [2] - International Industry plans to raise no more than 660 million yuan through a private placement to its controlling shareholder [2] - Ruima Precision has been awarded a project for automotive air suspension system products [2] - Wanhui High-tech expects a net profit increase of 69.81% to 109.77% for the first three quarters [2]

Policy Developments - The National Healthcare Security Administration (NHSA) has announced a public solicitation for information on innovative medical consumables, including brain-machine interface technologies and surgical robots, to streamline the coding process for these products [2] Drug and Device Approvals - Fosun Pharma's subsidiary, Fosun Kary, has had its drug registration application for Brexucabtagene Autoleucel accepted by the National Medical Products Administration, aimed at treating relapsed or refractory B-cell acute lymphoblastic leukemia in adults [4] - Novogene's subsidiary has received medical device registration certificates for several neurodiagnostic reagents, which can assist in diagnosing Alzheimer's and Parkinson's diseases [5] Capital Market Activities - Hengrui Medicine has signed a licensing agreement for its innovative drug SHR-A1811, receiving an upfront payment of $18 million and potential milestone payments up to $1.093 billion, which will enhance its overseas market presence [7] - Yong'an Pharmaceutical plans to acquire a 49.20% stake in its subsidiary Ling'an Technology for 27 million yuan, aiming to strengthen control and reduce management costs [8] Industry Events - The NHSA hosted discussions with domestic and international investment institutions, emphasizing support for the high-quality development of innovative drugs and the implementation of policies to facilitate this growth [10] - Illumina has announced partnerships with several global pharmaceutical companies to develop companion diagnostics based on its TruSight Oncology genomic testing platform, focusing on KRAS gene mutations [11] Regulatory and Governance Updates - The former deputy director of the Henan Provincial Medical Security Bureau is under investigation for serious violations of discipline and law [13] - Shareholder Wang Xiaopeng of Huyou Pharmaceutical plans to reduce his stake by up to 3% due to personal financial needs [14] - Independent director Huang Zhengming of Qidi Pharmaceutical has resigned due to work reasons, which may affect the board's composition [15]

Mergers and Acquisitions - Huatian Technology is planning to acquire Huy Microelectronics, a subsidiary of its controlling shareholder, through a share issuance and cash payment, which is expected to constitute a related party transaction but not a major asset restructuring. The company's stock will be suspended from trading starting September 25 [1] - Dalong Real Estate's subsidiary intends to acquire 60% equity of Beijing Chengzhu Real Estate Development Co., Ltd. from Beijing Shunyi New Town Development Co., Ltd. to enhance project reserves and operational capabilities [2] - Yong'an Pharmaceutical plans to acquire 49.2% equity of its subsidiary Hubei Ling'an Technology Co., Ltd. from minority shareholders for 27 million yuan, aiming for full ownership [3] - Rongxin Culture's wholly-owned subsidiary intends to acquire 51% equity of Wuhan Youxue Baobei Book Co., Ltd. for 16.32 million yuan, which will be consolidated into the company's financial statements post-transaction [4] Shareholding Changes - Huyou Pharmaceutical's shareholder Wang Xiaopeng plans to reduce his stake by up to 3%, equivalent to a maximum of 12.708 million shares [5] - Beimo High-tech's shareholder Chen Jianfeng intends to reduce his stake by up to 2.49%, which amounts to a maximum of 8.2666 million shares [6] - Donghua Energy's controlling shareholder, Mansen Energy (Zhangjiagang), has increased its stake by 0.34%, acquiring 5.3093 million shares for approximately 45.6488 million yuan [7] Risk Matters - Zhangjiang Hi-Tech has announced a potential irrational speculation risk as its stock price has deviated significantly from industry peers and the Shanghai Composite Index, with a cumulative price increase of 20% over three consecutive trading days [8] - *ST Gaohong faces a risk of delisting as its stock price has been below 1 yuan for 18 consecutive trading days, with a potential delisting if the market capitalization remains below 500 million yuan for 20 consecutive trading days [9] - *ST Yatai's controlling shareholder's voting rights have decreased due to a forced sale of shares by a court, although this will not lead to a change in control or governance structure at this time [10]

Mergers and Acquisitions - Huatian Technology is planning to acquire Huayi Microelectronics, a subsidiary of its controlling shareholder, through a combination of issuing shares and cash payment, which is expected to constitute a related party transaction but not a major asset restructuring. The company's stock will be suspended from trading starting September 25 [1] - Dalong Real Estate's subsidiary intends to acquire 60% equity of Beijing Chengzhu Real Estate Development Co., Ltd. from Beijing Shunyi New Town Development Co., Ltd. to enhance project reserves and operational capabilities [2] - Yong'an Pharmaceutical plans to purchase 49.2% equity of its subsidiary Hubei Ling'an Technology Co., Ltd. from minority shareholders for 27 million yuan, aiming for full ownership [3] - Rongxin Culture's wholly-owned subsidiary intends to acquire 51% equity of Wuhan Youxue Baobei Book Co., Ltd. for 16.32 million yuan, which will be consolidated into the company's financial statements post-transaction [4] Shareholding Changes - Huiyu Pharmaceutical's shareholder Wang Xiaopeng plans to reduce his stake by up to 3%, equating to a maximum of 12.708 million shares [5] - Beimo High-tech's shareholder Chen Jianfeng intends to reduce his stake by up to 2.49%, which amounts to a maximum of 8.2666 million shares [6] - Donghua Energy's controlling shareholder, Ma Sen Energy (Zhangjiagang), has increased its stake by 0.34%, acquiring 5.3093 million shares for approximately 45.6488 million yuan [7] Risk Matters - Zhangjiang Hi-Tech has announced a potential irrational speculation risk due to its stock price increasing significantly over three consecutive trading days, with a cumulative rise of 20% [8] - *ST Gaohong faces a risk of delisting as its stock price has been below 1 yuan for 18 consecutive trading days, with a potential delisting if the market capitalization remains below 500 million yuan for 20 consecutive trading days [9][10] - *ST Yatai's controlling shareholder's voting rights have decreased to 16.89% due to forced sale of shares, which may lower the control ratio of the actual controllers but will not lead to changes in company control or governance structure [11]

Group 1 - Donghua Energy's Masen increased its stake by 0.34% [1] - Guoxin Technology's shareholders plan to reduce their holdings by up to 4.5% [1] - Guoguang Electric's shareholders, including Guozhiguang and Tianyi Venture Capital, intend to reduce their holdings by up to 3.85% [1] Group 2 - Xincheng Technology's four shareholders plan to reduce their holdings by 2.0316% in March [1] - Yujing Co., Ltd.'s shareholder Que Shiquan Li No. 1 intends to reduce its holdings by no more than 4.28 million shares [1] - Huiyu Pharmaceutical's Wang Xiaopeng plans to reduce his holdings by 3% over three months [1] Group 3 - Huaxi Securities' Jianan Spring Company plans to reduce its holdings by 1% within three months [1] - Beimo Gaoke's Chen Jianfeng intends to reduce his holdings by 2.49% [1] - Maiqu'er's shareholders plan to reduce their total shareholding by no more than 2% [1] Group 4 - Huadong Heavy Machinery's Tianchen Jinting No. 1 intends to reduce its holdings by 1.00% [1] - Cangge Mining's Xinsha Hongyun Investment plans to reduce its holdings by 0.60% [1] - Shengke Communication's major fund's shareholding ratio has decreased to 15% [1]